Seerlinq
Seerlinq is an innovative company focused on developing breakthrough technologies in the field of medicine, with an emphasis on the diagnosis and monitoring of cardiovascular diseases. The company aims to improve healthcare quality through predictive, personalized, and preventive solutions that detect potential risks early and tailor diagnostic and treatment options for each patient. Their services include remote cardiology monitoring for heart failure patients, which is available free of charge in Slovakia, utilizing non-invasive, safe, and easy-to-use devices and AI-driven analysis to prevent hospitalizations and enhance patient life quality.
Industries
Nr. of Employees
small (1-50)
Seerlinq
Products
Non-invasive PPG-based home monitoring device
A patient-facing device designed to acquire photoplethysmographic signals (used alongside blood pressure and pulse-oximetry measurements) for remote hemodynamic assessment in the home setting.
Mobile health application and centralized analytics system
Mobile application for patient guidance and data upload, connected to a centralized database and analytics pipeline used by clinical teams and automated algorithms to monitor patient status.
AI-driven risk-prediction algorithms
Proprietary machine learning algorithms developed to detect risk of heart-failure deterioration and related adverse events from physiological signals; results reported in peer-reviewed publication(s).
Non-invasive PPG-based home monitoring device
A patient-facing device designed to acquire photoplethysmographic signals (used alongside blood pressure and pulse-oximetry measurements) for remote hemodynamic assessment in the home setting.
Mobile health application and centralized analytics system
Mobile application for patient guidance and data upload, connected to a centralized database and analytics pipeline used by clinical teams and automated algorithms to monitor patient status.
AI-driven risk-prediction algorithms
Proprietary machine learning algorithms developed to detect risk of heart-failure deterioration and related adverse events from physiological signals; results reported in peer-reviewed publication(s).
Services
A telemonitoring service that supplies a home measurement device and mobile application, collects measurements every other day, and provides continuous clinical oversight with clinician contact and treatment adjustment when deterioration is detected.
Provision of clinician reports, case discussions, and options for long-term collaboration to integrate remote monitoring outputs into physician care routines without adding workload.
A telemonitoring service that supplies a home measurement device and mobile application, collects measurements every other day, and provides continuous clinical oversight with clinician contact and treatment adjustment when deterioration is detected.
Provision of clinician reports, case discussions, and options for long-term collaboration to integrate remote monitoring outputs into physician care routines without adding workload.
Expertise Areas
- Remote patient monitoring (RPM) for heart failure
- PPG signal analysis for hemodynamic assessment
- AI-driven clinical risk prediction
- Clinical validation and evidence generation
Key Technologies
- Photoplethysmography (PPG)
- Pulse oximetry
- Mobile health application
- Cloud-based data collection and analytics
News & Updates
Seerlinq’s non-invasive technology was validated after 6 months of telemonitoring and presented in the ESC Late-Breaking Science session.
Seerlinq HeartCore is now a certified Class II(b) medical device under the EU MDR 2017/745 regulation.
More than 200 patients have joined the program, and over 50 physicians across Slovakia are collaborating with Seerlinq.
Recognition in the Deloitte Technology Fast 50 CE 2024 highlights innovation in healthcare.
Validation and presentation of Seerlinq's technology at ESC conference.
Certification of Seerlinq HeartCore as a Class II(b) medical device under EU MDR 2017/745.
Seerlinq’s non-invasive technology was validated after 6 months of telemonitoring and presented in the ESC Late-Breaking Science session.
Seerlinq HeartCore is now a certified Class II(b) medical device under the EU MDR 2017/745 regulation.
More than 200 patients have joined the program, and over 50 physicians across Slovakia are collaborating with Seerlinq.
Recognition in the Deloitte Technology Fast 50 CE 2024 highlights innovation in healthcare.
Validation and presentation of Seerlinq's technology at ESC conference.
Certification of Seerlinq HeartCore as a Class II(b) medical device under EU MDR 2017/745.